Pacific Biosciences/$PACB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pacific Biosciences
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Ticker
$PACB
Sector
Primary listing
Employees
575
Headquarters
Website
PACB Metrics
BasicAdvanced
$607M
-
-$1.83
2.17
-
Price and volume
Market cap
$607M
Beta
2.17
52-week high
$2.41
52-week low
$0.85
Average daily volume
8.3M
Financial strength
Current ratio
6.918
Quick ratio
5.807
Long term debt to equity
1,136.005
Total debt to equity
1,142.027
Interest coverage (TTM)
-63.63%
Profitability
EBITDA (TTM)
-225.738
Gross margin (TTM)
27.56%
Net profit margin (TTM)
-337.17%
Operating margin (TTM)
-398.23%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-33.28%
Return on equity (TTM)
-189.96%
Valuation
Price to revenue (TTM)
3.73
Price to book
9.87
Price to tangible book (TTM)
-2.22
Price to free cash flow (TTM)
-3.701
Free cash flow yield (TTM)
-27.02%
Free cash flow per share (TTM)
-0.546
Growth
Revenue change (TTM)
-17.35%
Earnings per share change (TTM)
21.07%
3-year revenue growth (CAGR)
3.81%
10-year revenue growth (CAGR)
6.90%
3-year earnings per share growth (CAGR)
24.52%
10-year earnings per share growth (CAGR)
8.28%
What the Analysts think about PACB
Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.
Bulls say / Bears say
PacBio reported stronger-than-expected preliminary Q1 2025 revenue of $36.9 million, beating expectations and demonstrating resilient demand for its sequencing consumables amidst funding headwinds. (Reuters)
The company’s cost-cutting measures, including eliminating approximately 120 positions to reduce annual adjusted operating expenses by $45 – $50 million while maintaining its full-year revenue forecast of $155 – $170 million, underscore disciplined financial management and preserve cash runway. (Reuters)
China’s ban on importing Illumina sequencers opens a significant market opportunity for PacBio to capture displaced demand in Greater China, a region accounting for roughly 7% of Illumina’s sales, potentially boosting PacBio’s instrument placements and consumables revenue. (Reuters)
Preliminary Q1 2025 revenue for PacBio fell 5% year-over-year to $36.9 million, highlighting its vulnerability to academic funding constraints and fluctuating instrument sales cycles. (Reuters)
The announced layoffs of approximately 120 positions reflect underlying financial strain and risk diminishing PacBio’s R&D and sales capabilities critical for future product development. (Reuters)
NIH’s policy to cap indirect cost reimbursement rates at 15%—down from around 27%—threatens to slash as much as $4 billion annually from research funding, intensifying cash flow pressure on academic and clinical customers that drive roughly one-fifth of PacBio’s revenue. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
PACB Financial Performance
Revenues and expenses
PACB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pacific Biosciences stock?
Pacific Biosciences (PACB) has a market cap of $607M as of October 26, 2025.
What is the P/E ratio for Pacific Biosciences stock?
The price to earnings (P/E) ratio for Pacific Biosciences (PACB) stock is 0 as of October 26, 2025.
Does Pacific Biosciences stock pay dividends?
No, Pacific Biosciences (PACB) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Pacific Biosciences dividend payment date?
Pacific Biosciences (PACB) stock does not pay dividends to its shareholders.
What is the beta indicator for Pacific Biosciences?
Pacific Biosciences (PACB) has a beta rating of 2.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.